HD12 for Advanced Stages

Phase 3

Completed

• Conditions: Hodgkin´s Lymphoma

• Registration Number: NCT00265031
• Lead Sponsor: University of Cologne

Brief Summary

This study is designed to test (1) whether the BEACOPP dosage can be reduced to baseline in the last 4 cycles without loss of effectiveness, and (2) whether consolidating irradiation is necessary following effective chemotherapy.

Detailed Description

Not available

Study Timeline

• Study Start: 1999-01
• Study First Submitted: 2005-12-12
• Study First Submitted QC: 2005-12-12
• Study First Posted: 2005-12-13
• Status Verified: 2007-08
• Last Update Submitted: 2012-06-22
• Last Update Posted: 2012-06-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Hodgkin´s lymphoma (histologically proven)

• CS(PS) IIB with one or both of the risk factors:

  1. bulky mediastinal mass (> 1/3 of maximum transverse thorax diameter)
  2. extranodal involvement

• CS(PS) III, IV

• written informaed consent

Exclusion Criteria

• Leukocytes <3000/microl
• Platelets <100000/microl
• Hodgkin´s Disease as "composite lymphoma"
• Activity index (WHO) < grade 2

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: FACTORIAL